Literature DB >> 22672294

Marathon of eponyms: 26 Zinsser-Engman-Cole syndrome (Dyskeratosis congenita).

C Scully1, J Langdon, J Evans.   

Abstract

The use of eponyms has long been contentious, but many remain in common use, as discussed elsewhere (Editorial: Oral Diseases. 2009: 15; 185). The use of eponyms in diseases of the head and neck is found mainly in specialties dealing with medically compromised individuals (paediatric dentistry, special care dentistry, oral and maxillofacial medicine, oral and maxillofacial pathology, oral and maxillofacial radiology and oral and maxillofacial surgery) and particularly by hospital-centred practitioners. This series has selected some of the more recognised relevant eponymous conditions and presents them alphabetically. The information is based largely on data available from MEDLINE and a number of internet websites as noted below: the authors would welcome any corrections. This document summarises data about Zinsser-Engman-Cole syndrome.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22672294     DOI: 10.1111/j.1601-0825.2009.01558.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  4 in total

1.  Tongue ulcer in a case of X-linked diskeratosis congenita.

Authors:  E Baruzzi; F Astolfi; A Trapani; S Sutera; G Lodi
Journal:  Ann Stomatol (Roma)       Date:  2013-10-24

Review 2.  Oral potentially malignant disorders: an overview of more than 20 entities.

Authors:  Hamed Mortazavi; Maryam Baharvand; Masoumeh Mehdipour
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2014-03-05

3.  Prognosis and predictive value of heat-shock proteins expression in oral cancer: A PRISMA-compliant meta-analysis.

Authors:  Wei Lu; Yongwu Wang; Min Gan; Qingyun Duan
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

4.  Prognostic and clinical implications of c-erbB-2 expression in patients with oral cancer: A meta-analysis.

Authors:  Ying Meng; Peng Yang; Lili Ma
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.